ArticleInternational journal of cancer2026
Evaluating distant recurrence-free survival and location of metastasis in HER2+ breast cancer by ER status.
Article in International journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Prognostic impact of extensive nodal involvement in small-sized (T1) breast cancer: a population-based and propensity score-matched analysis of the SEER database.Gland surgery · 2026Article
- Evaluating distant recurrence-free survival and location of metastasis in HER2+ breast cancer by ER status.International journal of cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Prognostic factors, such as the Human Epidermal growth factor Receptor 2 (HER2) and Estrogen Receptor (ER) influence distant recurrence-free survival (RFS) in breast cancer. This study aims to evaluate the interaction between HER2 and ER status with RFS, and if that interaction influences where the metastasis is located. To do this, we used a study population of all women diagnosed with non-metastatic, invasive breast cancer in Stockholm from 2007 to 2020. Flexible parametric survival models were used to estimate time-varying survival and hazard ratios (HR) for RFS. Cumulative incidence was used to quantify rates of metastasis in key locations. We found significant interactions between ER and HER2 for RFS (p = 0.037), which was time varying (p = 0.017). For ER+ patients, adjusted short-term survival at 2.5 years after diagnosis was identical for HER2+ compared to HER2- patients (HR 1.02, CI; 0.76-1.39), but was dramatically better for HER2+ patients after 5 years (HR at 7.5 years 0.29, CI; 0.14-0.58). In contrast, among ER- patients, HER2+ patients experienced constant risk compared to HER2- from diagnosis until the end of the study (HR ~0.50). Finally, we observed that HER2+ patients have a higher rate of first metastasis to the brain than HER2- patients (p < 0.001). Our study demonstrates that the interaction between ER and HER2 status has a time-varying impact on RFS and plays a role in determining the location of metastasis. Thus, the utilization of complex models that combine ER and HER2 status can enhance the understanding of patient RFS and the likelihood of metastasis in specific locations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.